Positive Interim Phase I Results of Zolmitriptan Transdermal Microporation System for the Treatment of Acute Migraine
SAN DIEGO, March 29, 2024. PassPort Technologies, Inc. (PPTI), based in San Diego, a clinical-stage drug and medical device development company, today announced positive interim results from the Phase 1 (Part A) clinical trial of Zolmitriptan... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 29, 2024 Category: Pharmaceuticals Source Type: clinical trials
Bimekizumab in Plaque Psoriasis
Conditions: Plaque Psoriasis Interventions: Drug: Bimekizumab Sponsors: Icahn School of Medicine at Mount Sinai; UCB Pharma; Psoriasis Treatment Center of Central New Jersey Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 28, 2024 Category: Research Source Type: clinical trials
FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma
Conditions: Head and Neck Squamous Cell Carcinoma Interventions: Drug: FID007 Sponsors: Fulgent Pharma LLC. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2024 Category: Research Source Type: clinical trials
A Phase 3 Single-arm Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
Conditions: Bladder Cancer; Urothelial Carcinoma; Urothelial Carcinoma Bladder Interventions: Drug: UGN-103 Sponsors: UroGen Pharma Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 26, 2024 Category: Research Source Type: clinical trials
A Phase 4 Study Evaluating the Safety of the Nasal Pump
Conditions: Dry Eye; Kerato Conjunctivitis Sicca Interventions: Drug: Tyrvaya Nasal Pump Sponsors: Oyster Point Pharma, Inc. Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 26, 2024 Category: Research Source Type: clinical trials
Johnson & Johnson's Nipocalimab Granted U.S. FDA Fast Track Designation to Reduce the Risk of Fetal Neonatal Alloimmune Thrombocytopenia (FNAIT) in Alloimmunized Pregnant Adults
SPRING HOUSE, Pa. March 26, 2024– Johnson& Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation (FTD) for nipocalimab to reduce the risk of FNAIT in alloimmunizeda pregnant adults... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 26, 2024 Category: Pharmaceuticals Source Type: clinical trials
Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi Syndrome
CHATHAM, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced the U.S. Food... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 25, 2024 Category: Pharmaceuticals Source Type: clinical trials
Phase 2b Study Evaluating the Safety and Efficacy of AP01 in Participants With PPF
Conditions: Progressive Pulmonary Fibrosis Interventions: Drug: AP01; Other: Placebo Sponsors: Avalyn Pharma Inc.; DevPro Biopharma Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 25, 2024 Category: Research Source Type: clinical trials
A Study Evaluating the Safety and Efficacy of AP01 in Participants With Progressive Pulmonary Fibrosis (PPF)
Conditions: Progressive Pulmonary Fibrosis Interventions: Drug: AP01; Other: Placebo Sponsors: Avalyn Pharma Inc.; DevPro Biopharma Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 25, 2024 Category: Research Source Type: clinical trials
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that AXS-12... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 25, 2024 Category: Pharmaceuticals Source Type: clinical trials
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced topline... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 25, 2024 Category: Pharmaceuticals Source Type: clinical trials
Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome
BEDFORD, Mass.--(BUSINESS WIRE)--Mar. 25, 2024-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 25, 2024 Category: Pharmaceuticals Source Type: clinical trials
Invivyd Announces FDA Authorization for Emergency Use of Pemgarda (Formerly VYD222) for Pre-Exposure Prophylaxis (PrEP) of COVID-19
WALTHAM, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that Pemgarda™ (pemivibart), formerly... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 22, 2024 Category: Pharmaceuticals Source Type: clinical trials
Otsuka Announces Interim Data from Phase 2b/c Trial Indicating New Investigational Compound May Shorten Tuberculosis Treatment
Princeton, N.J. and Tokyo, Japan– March 21, 2024– Otsuka Pharmaceutical Development& Commercialization, Inc., and our parent company Otsuka Pharmaceutical, Co. Ltd., announce that interim data from a Phase 2b/c trial exploring... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 21, 2024 Category: Pharmaceuticals Source Type: clinical trials
Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma
BASKING RIDGE, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the“Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 21, 2024 Category: Pharmaceuticals Source Type: clinical trials
